Sp626

PRESENTATION OF CLINICAL PRACTICE (CP) SECTION RESEARCH MENTOR AWARD: ROBERT (ROCKY) E. SCHOEN, MD, MPH

Date
May 19, 2024

Presenters

Speaker Image for Gary Falk
Unversity of Pennsylvania
Speaker Image for Aasma Shaukat
New York University
Speaker Image for Robert Schoen

Tracks

Related Products

Thumbnail for PRESENTATION OF CLINICAL PRACTICE (CP) RESEARCH MENTOR AWARD: DOUGLAS J. ROBERTSON, MD, MPH, AGAF
Thumbnail for INCREASED REFLUX SECONDARY BILE ACIDS ARE ASSOCIATED WITH SHIFTS TO THE MICROBIOME AND TRANSCRIPTOME IN BARRETT’S ESOPHAGUS
INCREASED REFLUX SECONDARY BILE ACIDS ARE ASSOCIATED WITH SHIFTS TO THE MICROBIOME AND TRANSCRIPTOME IN BARRETT’S ESOPHAGUS
Background: Bile acids comprise a major component of refluxate in GERD, the major risk factor for Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). Bile acids are metabolized by bacteria, and bacterial composition is also impacted by exposure to bile acids…
Thumbnail for FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
FLUTICASONE PROPRIONATE ORAL DISINTEGRATING TABLET, APT-1011, IMPROVES FIBROSTENOTIC FEATURES OF STRICTURES AND GRADE 2/3 RINGS IN SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
Esophageal eosinophilic inflammation and remodeling lead to fibrostenosis in many patients with eosinophilic esophagitis (EoE)…
Thumbnail for THE TISSUE SYSTEMS PATHOLOGY TEST ENABLES RISK-ALIGNED MANAGEMENT FOR PATIENTS WITH BARRETT’S ESOPHAGUS
THE TISSUE SYSTEMS PATHOLOGY TEST ENABLES RISK-ALIGNED MANAGEMENT FOR PATIENTS WITH BARRETT’S ESOPHAGUS
INTRODUCTION: The goal of Barrett’s esophagus (BE) surveillance is to detect dysplasia and esophageal adenocarcinoma (EAC) at early, treatable stages…